Vancouver, British Columbia--(Newsfile Corp. - July 16, 2025) - Comprehensive Healthcare Systems Inc. (TSXV: CHS) ("CHS" or the "Company"), a leading Software-as-a-Service (SaaS) provider revolutionizing healthcare benefits administration, is pleased to announce key milestones achieved during the first half of 2025 and provide an update on its status and future growth strategy. Through its innovative Novus 360 platform, CHS continues to drive efficiency, transparency, and cost savings for Insurance Provide ...

For further information Contact: Krysta Larson (651) 355-4587 Krysta.Larson@chsinc.com CHS Reports $232.2 Million in Fiscal 2025 Third-Quarter Net Income Strong spring agronomy season lifts ag results ST. PAUL, MINN. (July 9, 2025) - CHS Inc., the nation's leading agribusiness cooperative, today released results for its third quarter of fiscal year 2025. The company reported net income of $232.2 million and revenues of $9.8 billion for the quarter that ended May 31, 2025, compared to net income of $297.3 mi ...

Financial Performance - Revenues for the three months ended May 31, 2025, were $9,766,421 thousand, a slight increase from $9,608,983 thousand in 2024, representing a growth of 1.6%[120] - Gross profit decreased to $329,811 thousand in 2025, down from $467,795 thousand in 2024, reflecting a gross margin decline from 4.9% to 3.4%[120] - Net income attributable to CHS Inc. was $232,184 thousand for the three months ended May 31, 2025, compared to $297,274 thousand in 2024, a decrease of 21.9%[120] - Revenues for the nine months ended May 31, 2025, were $26,856,724, a decrease of 10.5% from $30,087,121 in 2024[163] - Gross profit for the same period was $806,802, representing 3.0% of revenues, down from 4.9% in 2024[163] - Net income attributable to CHS Inc. for the nine months ended May 31, 2025, was $401,220, a decline of 59.5% from $990,504 in 2024[163] Segment Performance - The Energy segment reported a loss before income taxes of $50,088 thousand in 2025, a significant decline from income of $97,850 thousand in 2024, representing a change of 151.2%[125] - The Ag segment's income before income taxes increased by 39.2% to $151,040 thousand in 2025 from $108,535 thousand in 2024[131] - Revenues in the Ag segment rose to $7,962,254 thousand in 2025, an increase of 5.8% from $7,523,656 thousand in 2024[142] - The Energy segment reported a loss before income taxes of $416,264 for the nine months ended May 31, 2025, compared to a loss of $113,794 in 2024, reflecting a change of 127.3%[169] - Revenues in the Energy segment decreased by 14.3% to $6,541,840 in 2025 from $7,475,532 in 2024[181] - The Ag segment revenues fell by 9.8% to $21,189,835 in 2025 from $23,486,932 in 2024[185] Market Conditions - CHS Inc. reported a decrease in total refinery throughput volumes to 116,487 barrels per day in Q3 2025, down from 192,900 barrels per day in Q3 2024[115] - The company anticipates continued margin pressure in energy and agricultural commodities through at least the remainder of fiscal 2025 due to macroeconomic factors[111] - CHS Inc. expects global economic factors impacting energy and agricultural commodities to be less favorable in fiscal 2025 compared to fiscal 2024[111] - Average market prices for corn decreased to $4.56 per bushel in Q3 2025 from $4.43 per bushel in Q3 2024, while soybean prices fell to $10.30 per bushel from $11.81 per bushel[119] Expenses and Costs - Marketing, general and administrative expenses decreased by 18.2% to $258,850 thousand in 2025 from $316,435 thousand in 2024, primarily due to lower performance-based incentive compensation[157] - Interest expense increased by 88.3% to $44,109 thousand in 2025 from $23,425 thousand in 2024, attributed to a higher short-term notes payable balance[158] - Cost of goods sold in the Energy segment decreased by 6.6% to $1,760,043 thousand in 2025 from $1,885,415 thousand in 2024, driven by an oversupply in the market[149] - Marketing, general and administrative expenses decreased by 11.2% to $769,968 in 2025 from $866,721 in 2024, mainly due to lower performance-based compensation[199] - Interest expense increased by 23.5% to $96,962 in 2025 from $78,513 in 2024, attributed to a higher short-term notes payable balance[200] Cash Flow and Capital Expenditures - Cash and cash equivalents decreased from $794.9 million to $323.9 million from August 31, 2024, to May 31, 2025[205] - Working capital decreased by $741.2 million to $2.57 billion as of May 31, 2025, driven by increased current liabilities[210] - Total capital expenditures for fiscal 2025 are expected to be approximately $735.4 million, down from $808.8 million in fiscal 2024[207] - Net cash used in operating activities was $635.3 million for the nine months ended May 31, 2025, a decrease of $795.0 million year-over-year[213] Investments and Acquisitions - The company acquired WCAS for an estimated cash purchase price of $322.1 million, enhancing its grain and agronomy platforms[207] - Equity income from investments rose by 34.6% to $204,605 thousand in 2025, compared to $151,999 thousand in 2024, mainly due to a gain on the sale of a business by Ventura Foods[160] - Equity income from investments increased by $45.8 million (12.3%) to $419.0 million for the nine months ended May 31, 2025, mainly due to a gain on the sale of a business by Ventura Foods[202][203] Tax and Other Income - The effective tax rate increased to 10.5% in 2025 from 4.1% in 2024, primarily due to changes in state law affecting tax credits[162] - Income tax expense rose by $10.3 million (48.1%) to $31.7 million for the nine months ended May 31, 2025, attributed to reduced research and development tax credits and changes in state law[204] - Other income decreased by $31.7 million (29.9%) to $105.8 million for the nine months ended May 31, 2025, primarily due to decreased interest income from a smaller cash balance[201] Strategic Outlook - The company plans to pursue growth through strategic investments and cooperative connections despite less favorable market conditions[112] - The company redeemed $271.0 million of member equity during the nine months ended May 31, 2025, as part of its equity redemption strategy[208] - No material changes in market risk exposures were experienced for the period ended May 31, 2025[222] - The company refers to Note 1 for applicable standards issued and not yet adopted[221]

Core Insights - Coherus BioSciences has completed its strategic transformation to focus on innovative oncology, particularly through the commercialization of LOQTORZI and the advancement of its immuno-oncology pipeline [1][2] Recent Business Highlights - The divestiture of UDENYCA in April 2025 allows Coherus to concentrate on its oncology portfolio, with LOQTORZI revenues expected to be maximized [2] - LOQTORZI net revenue for Q1 2025 was $7.3 million, with patient demand increasing over 15% compared to Q4 2024 [5][9] - The National Comprehensive Cancer Network (NCCN) has designated LOQTORZI as the only treatment with Preferred status for nasopharyngeal carcinoma (NPC) [5] Financial Performance - Net revenue from continuing operations for Q1 2025 was $7.6 million, up from $2.3 million in Q1 2024, primarily due to higher LOQTORZI sales [9] - Research and development expenses decreased to $24.4 million in Q1 2025 from $28.4 million in Q1 2024, attributed to reduced co-development costs and personnel savings [11] - The company reported a net loss from continuing operations of $47.4 million, or $(0.41) per share, compared to a loss of $68.0 million, or $(0.60) per share, in the same period last year [15][16] Pipeline Development - Coherus is advancing its next-generation immuno-oncology pipeline, including CHS-114, which is currently in Phase 1 clinical trials [4][12] - Promising early clinical data for CHS-114 was presented at the AACR Annual Meeting, showing potential for treating various solid tumors [12] - Enrollment is ongoing for a Phase 2 trial of casdozokitug in combination with toripalimab and bevacizumab for first-line hepatocellular carcinoma (HCC), with data readout expected in 1H 2026 [4][12] Cash Position - As of March 31, 2025, cash and cash equivalents totaled $82.4 million, down from $126.0 million at the end of 2024 [18] - The company received an upfront payment of $483.4 million from the divestiture of the UDENYCA franchise, which will be reflected in Q2 2025 financials [18]